Glycemic control in patients with diabetes mellitus on hemodialysis
- 作者: Lobanova K1, Severina A1, Martinov S1, Shamkhalova M1, Shestakova M1
-
隶属关系:
- Endocrinology Research Centre
- 期: 卷 91, 编号 10 (2019)
- 页面: 124-134
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33718
- DOI: https://doi.org/10.26442/00403660.2019.10.000352
- ID: 33718
如何引用文章
全文:
详细
作者简介
K Lobanova
Endocrinology Research Centre
Email: miss.sapog@mail.ru
клинический ординатор; ORCID: 0000-0002-3656-0312 Moscow, Russia
A Severina
Endocrinology Research Centreк.м.н., с.н.с., врач-эндокринолог отд-ния диабетической болезни почек и посттрансплантационной реабилитации Института диабета «НМИЦ эндокринологии» Moscow, Russia
S Martinov
Endocrinology Research Centreд.м.н., в.н.с., врач-нефролог, зав. кабинетом экстракорпоральных методов лечения почечной патологии «НМИЦ эндокринологии» Moscow, Russia
M Shamkhalova
Endocrinology Research Centreд.м.н., зав. отд-нием диабетической болезни почек и посттрансплантационной реабилитации Института диабета «НМИЦ эндокринологии» Moscow, Russia
M Shestakova
Endocrinology Research Centreд.м.н., проф., академик РАН, директор ФГБУ «НМИЦ эндокринологии», директор Института диабета ФГБУ «НМИЦ эндокринологии» Moscow, Russia
参考
- Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет. 2018;21(3):160-9. doi: 10.14341/DM9392
- Томилина Н.А., Андрусев А.М., Перегудова Н.Г. и др. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 2010-2015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Часть первая. М., 2017. doi: 10.28996/1680-4422-2017-4Suppl-1-95
- Дедов И.И., ред. Диализная терапия у больных с сахарным диабетом. М.: Министерство здравоохранения и социального развития Российской Федерации, 2009.
- Abe M, Kalantar-Zadeh K. Haemodialysis - induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302-13. doi: 10.1038/nrneph.2015.38
- Wakino S, Minakuchi H, Miya K, et al. Aldosterone and Insulin Resistance: Vicious Combination in Patients on Maintenance Hemodialysis. Ther Apher Dial. 2018;22(2):142-51. doi: 10.1111/1744-9987.12632
- Sudha M.J, Salam H.S, Viveka S, et al. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8(1):64-8. doi: 10.4103/0976-9668.198348
- Sobngwi E, Enoru S, Ashuntantang G, et al. Day - to - day variation of insulin requirements of patients with type 2 diabetes and end - stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409-12. doi: 10.2337/dc09-2176
- Nakao T, Inaba M, Abe M, et al. Best practice for diabetic patients on hemodialysis 2012. Ther Apher Dial. 2015;19 Suppl 1:40-66. doi: 10.1111/1744-9987.12299
- Guthoff M, Wagner R, Vosseler D, et al. Impact of end - stage renal disease on glucose metabolism - a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670-6. doi: 10.1093/ndt/gfx018
- Rhee C.M, Leung A.M, Kovesdy C.P, et al. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135-45. doi: 10.1111/sdi.12198
- Tzamaloukas A.H. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Peritoneal Dial. 1996;12:171-5.
- Sinha N, Mishra T.K, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1 levels. Ann Lab Med. 2012;32:17-22.
- Sharif A, Baboola K. Diagnostic application of the A1 assay in renal disease. J Am Soc Nephrol. 2010;21:383-94.
- Park J, Lertdumrongluk P, Molnar M.Z, et al. Glycemic control in diabetic dialysis patients and the burnt - out diabetes phenomenon. Curr Diab Rep. 2012;12(4):432-9. doi: 10.1007/s11892-012-0286-3
- Ricks J, Molnar M.Z, Kovesdy C.P, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61(3):708-15. doi: 10.2337/db11-1015
- Abe M, Hamano T, Hoshino J, et al. Is there a "burnt - out diabetes" phenomenon in patients on hemodialysis? Diabetes Res Clin Pract. 2017;130:211-20. doi: 10.1016/j.diabres.2017.06.012
- Hoshino J, Larkina M, Karaboyas A, et al. Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients. Kidney Int. 2017;92(2):497-503. doi: 10.1016/j.kint.2017.02.008
- Ramirez S.P, Mc Cullough K.P, Thumma J.R, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care. 2012;35(12):2527-32. doi: 10.2337/dc12-0573
- Yoo D.E, Park J.T, Oh H.J, et al. Good glycemic control is associated with better survival in diabetic patients on peritoneal dialysis: a prospective observational study. PLoS One. 2012;7(1):e30072. doi: 10.1371/journal.pone.0030072
- Kim Y, Park J.C, Molnar M.Z, et al. Correlates of low hemoglobin A1c in maintenance hemodialysis patients. Int Urol Nephrol. 2013;45(4):1079-90. doi: 10.1007/s11255-012-0208-y
- Bedi R, Dr Chowdhury T.A, El-Sherbini N, et al. JBDS-IP Management of adults with diabetes on the haemodialysis unit. 2016 Apr. Brit J Diabetes. 2016 Apr.;16(2):69-77.
- American Diabetes Association. Standarts of Medical Care in Diabetes - 2018. Diabetes Care. 2018:41(S.1). doi: 10.2337/dc18-Sint01
- Дедов И.И., Шестакова М.В., Майоров А.Ю., ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. M.: Министерство здравоохранения и социального развития Российской Федерации, 2017.
- Новицкий В.В., Гольдберг Е.Д. и др., ред. Патофизиология. М.: ГЭОТАР-Медиа, 2009. Т. 1. 848 с. Глава 12.6.5.
- Андрушкевич В.В. Биохимические показатели крови, их рефересные значения, причины изменения уровня в сыворотке крови. Новосибирск, 2006. 29 с.
- Shafi T, Sozio S.M, Plantinga L.C, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 2013;36(6):1522-33. doi: 10.2337/dc12-1896
- Okada T, Nakao T, Matsumoto H, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end - stage renal disease. Intern Med. 2007;46:807-14.
- Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long - term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton). 2008;13:278-83. doi: 10.1111/j.1440-1797.2007.00864.x
- Klonoffa D.C, Ahnb D, Drincicc A. Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Res Clin Pract. 2017;133:178-92. doi: 10.1016/j.diabres.2017.08.005
- Gai M, Merlo I, Dellepiane S, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif. 2014;38(1):68-73. doi: 10.1159/000362863
- Képénékian L, Smagala A, Meyer L, et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol. 2014;82(4):240-6. doi: 10.5414/CN108280
- Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107(3):348-54. doi: 10.1016/j.diabres.2015.01.026
- Ólafsdóttir A.F, Polonsky W, Bolinder J, et al. A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technol Ther. 2018;20(4):274-84. doi: 10.1089/dia.2017.0363
- Mirani M, Berra C, Finazzi S, et al. Inter - day glycemic variability assessed by continuous glucose monitoring in insulin - treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12(10):749-53. doi: 10.1089/dia.2010.0052
- Heinemann L, Freckmann G, Ehrmann D, et al. Real - time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367-77. doi: 10.1016/S0140-6736(18)30297-6
- Marbury T.C, Ruckle J.L, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000;67(1):7-15. doi: 10.1067/mcp.2000.103973
- Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26(3):886-91.
- Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2013;5(1):10. doi: 10.1186/1758-5996-5-10
- Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end - stage renal disease: a pilot study. PLoS One. 2014;9(12):e113468. doi: 10.1371/journal.pone.0113468
- Idorn T, Knop F.K, Jørgensen M.B, et al. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016;39(2):206-13. doi: 10.2337/dc15-1025
- Park S.H, Nam J.Y, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore). 2016;95(32):e4543. doi: 10.1097/MD.0000000000004543
- Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015;6(6):840-9. doi: 10.4239/wjd.v6.i6.840
- Padmanabhan A, Velayudham B, Vijaykumar N, et al. Evaluation of glycemic status during the days of hemodialysis using dialysis solutions with and without glucose. Saudi J Kidney Dis Transpl. 2018;29(5):1021-7. doi: 10.4103/1319-2442.243951
- Burmeister J.E, Miltersteiner Dda R, Burmeister B.O, et al. Risk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre - dialysis glycemia. Arch Endocrinol Metab. 2015;59(2):137-40. doi: 10.1590/2359-3997000000026
- Burmeister J.E, Scapini A, da Rosa Miltersteiner D, et al. Glucose - added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol Dial Transplant. 2007;22(4):1184-9. doi: 10.1093/ndt/gfl710
- Raimann J.G, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27(4):1559-68. doi: 10.1093/ndt/gfr520